In targeted therapies, drugs are used to “target” cancerous cells without having an adverse impact on normal cells during cancer treatments. In the healthcare industry, finding new targets and producing drugs for those targets have been a challenging and competitive task for the drugmakers.
Hansoh Pharmaceutical is one such company, located in east China’s Nanjing City, which is working for the aforementioned cause. The company, in 2019, made its IPO in Hong Kong which, according to the CEO of the firm, was an essential deed for it to be a strong competitor in the global market.
Apart from research and development, Chinese pharmaceutical companies, with the intention to get themselves recognized in foreign markets, are increasingly carrying out overseas clinical trials. They are increasingly going public overseas.
Prof. Lu Shun, Director of Lung Cancer Professional Committee of Chinese Medical Association, also expressed his views on China’s pharmaceutical industry going global. He said that the Chinese pharmaceutical enterprises would be conducting research and development for new drugs under international unified standards making everyone follow the same standards and rules, if the industry makes its place in global market.
Chinese pharma companies had registered over 30 overseas clinical trials in the first half of 2021, according to the data provided by China News of Drug Information Association.
Genetron Holdings Ltd., BeiGene Ltd. and Zai Lab Ltd. are the three Chinese firms that were listed on the NASDAQ by the end of year 2020.